to remain at target This recommendation assumes that improved disease control with DMARDs should allow less use of glucocorticoids. The recommendation is conditional because the continued use of glucocorticoids may be required for patients who do not respond to DMARDs even after maximizing methotrexate dosage and switching DMARD classes. Addition of/switching to DMARDs (with or without intraarticular [IA] glucocorticoids) is conditionally recommended over the use of IA glucocorticoids alone for